Targeted delivery of Rab26 siRNA with precisely tailored DNA prism for lung cancer therapy.
In this study, a GTPase Rab26 was explored as a new potential therapeutic target using precisely tailored DNA prism for targeted lung cancer therapy. Specifically, a DNA prism platform with tunable targeting and siRNA loading capability is designed and synthesized. The DNA prisms were decorated with two functional units: a Rab26 siRNA as the drug and MUC-1 aptamers as targeting moiety for non-small cell lung cancer. The number and position of both siRNA and MUC-1 aptamer can be readily tuned. Native polyacrylamide gel electrophoresis (PAGE) and dynamic light scattering technique (DLS) demonstrate that all nanoprisms with different functionalities are self-assembled with high yield. It is also found that the cellular uptake of DNA prims is proportional to the aptamer number on each nanoprism, and the as-prepared DNA nanoprism show excellent anti-cancer activities and targeting capability. Current study suggest that by careful design, self-assembled DNA nanostructures are highly promising, customizable, multifuncitonal nanoplatform for potential biomedical applications, such as personalized precision therapy in the near future. PMID: 30610755 [PubMed - as supplied by publisher]
In conclusion, AFAP1-AS1 promoted chemotherapy resistance by supressing miR-139-5p expression and promoting RRM2/EGFR/AKT signaling pathway in NSCLC cells.
Conclusions: Crizotinib was effective and well tolerated in Chinese patients with ALK-positive, advanced NSCLC in real-world clinical practice. For patients without BBM, crizotinib as first-line therapy can lead to a longer PFS than second-or later line therapy. CBPD plus local therapy after 1st PD beyond crizotinib is feasible and effective in clinical routine practice.
Dr Tony Mok of Hong Kong University reviews key studies on non-small cell lung cancer therapies, presented at the 2019 annual meeting of the European Society for Medical Oncology (ESMO).Medscape
A liquid biopsy may be able to predict the efficacy of EGFR-targeted tyrosine kinase inhibitors in patients with non –small cell lung cancer.
AbstractBackgroundIt has been reported that 20% of lung cancer patients have renal impairment caused by chronic kidney disease (CKD). Since docetaxel is predominantly excreted by the hepatobiliary system, it is administered to non ‐small cell lung cancer (NSCLC) patients with renal impairment. However, few clinical data are available on the toxicity and efficacy of docetaxel for patients with nondialysis renal impairment. Furthermore, some cases of tubular nephrotoxicity caused by docetaxel in NSCLC patients have been repor ted. Therefore, a retrospective cohort study was conducted to assess the influence of nondialysis ...
les Ricordel Non-small cell lung cancer (NSCLC) has been the leading cause of cancer-related death worldwide, over the last few decades. Survival remains extremely poor in the metastatic setting and, consequently, innovative therapeutic strategies are urgently needed. Inhibitor of Growth Gene 2 (ING2) is a core component of the mSin3A/Histone deacetylases complex (HDAC), which controls the chromatin acetylation status and modulates gene transcription. This gene has been characterized as a tumor suppressor gene and its status in cancer has been scarcely explored. In this review, we focused on ING2 and other mSin3A/HDAC ...
Lung cancer is one of the leading causes of death worldwide . Approximately 80% of lung cancer patients are consistent with non-small cell histology (NSCLC) . The Tumor-Node-Metastasis (TNM) system is used to classify and stratify patients by prognosis according to tumor size (T), lymph node (LN) involvement (N) and presence of distant metastases (M). Its actual valid 8th edition was implemented in 2016 using clinical information from 70,976 consecutive NSCLC patients treated between 1999 and 2010 in 16 countries .
AbstractBackgroundIt is known that there are insufficient prognostic factors for non-small cell lung cancer (NSCLC). It was reported that PD-L1 was a prognostic factor for NSCLC,and c-Myc regulated the expression of PD-L1. Herein, we investigated c-Myc and PD-L1 expression and their association with overall survival (OS) in NSCLC.MethodsFormalin-fixed paraffin-embedded specimens were obtained from 128 patients with surgically resected primary NSCLC. Immunohistochemistry was used to assess the expression of PD-L1 and c-Myc in this study. Pearson ’s Chi squared test or Fisher’s exact test was used to analyze the ...
Publication date: Available online 19 October 2019Source: The Annals of Thoracic SurgeryAuthor(s): Melanie P. Subramanian, Graham A. Colditz